|Bid||5.71 x 4000|
|Ask||6.39 x 3100|
|Day's Range||5.79 - 6.07|
|52 Week Range||3.95 - 19.94|
|Beta (3Y Monthly)||2.04|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
GHENT, Belgium, Aug. 19, 2019 /PRNewswire/ -- ActoBio Therapeutics, Inc., a wholly owned subsidiary of Intrexon Corporation (XON) and innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents, announced that the U.S. Food and Drug Administration (FDA) has given its permission to an Investigational New Drug (IND) application for AG017, an innovative orally-delivered therapeutic candidate for the treatment of celiac disease. ActoBio Therapeutics™ is dedicated to developing and commercializing the next generation of oral antigen-specific immunotherapy utilizing its proprietary delivery vehicle.
- Quarterly GAAP revenues of $36.0 million and net loss attributable to Intrexon of $38.8 million including non-cash charges of $8.0 million - GERMANTOWN, Md. , Aug. 8, 2019 /PRNewswire/ -- Intrexon Corporation ...
- Milestone represents the first patient dosed with UltraCAR-T targeting solid tumors - First-in-class investigational therapy using autologous CAR-T cells targeting advanced, recurrent platinum resistant ...
Intrexon (XON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GERMANTOWN, Md. , Aug. 1, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ...
Intrexon Corporation (NASDAQ:XON) is a small-cap stock with a market capitalization of US$1.2b. While investors...
GHENT, Belgium, July 1, 2019 /PRNewswire/ -- ActoBio Therapeutics, Inc., a wholly owned subsidiary of Intrexon Corporation (XON) and innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents, has announced that it will progress to the next stage of the Phase Ib/IIa clinical trial for investigational drug AG019 for the treatment of early-onset type 1 diabetes (T1D). This follows a scheduled review by the independent Data and Safety Monitoring Board, which supported moving forward with the study.
GERMANTOWN, Md., June 26, 2019 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (XON) and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced that the first patient has been dosed with PRGN-3006, a first-in-class investigational therapy using Precigen's non-viral UltraCAR-T™ therapeutic platform. PRGN-3006 UltraCAR-T is an autologous chimeric antigen receptor T (CAR-T) cell therapy under investigation for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or higher risk myelodysplastic syndrome (MDS) (clinical trial identifier: NCT03927261).
Intrexon (XON) inks a $100-million worth exclusive licensing deal with Surterra to produce cannabinoid in a reliable and cost-effective fashion, using its own yeast fermentation process. Shares climb.
Intrexon Corporation (NASDAQ: XON) announced a 0 million partnership with Surterra Wellness to advance its cannabinoid production. The companies will join forces to push forward Surterra's cannabinoid production at a cost-effective, industrial scale utilizing Intrexon's proprietary yeast fermentation platform. Need more cannabis news?
Exclusive Global Agreement to Transform Surterra's Ability to Produce Specific Cannabinoids to Meet Growing Demand, Boost Innovation and Product Development BUDAPEST, Hungary and ATLANTA , June 18, 2019 ...
Intrexon Corp NASDAQ/NGS:XONView full report here! Summary * Bearish sentiment is high and has been increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is high for XON with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting XON. Sentiment has worsened and traders added to their bearish short positions on June 14. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold XON had net inflows of $1.57 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
GERMANTOWN, Md. , June 13, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ...
CEO of Intrexon Corp (NASDAQ:XON) Randal J Kirk bought 483,268 shares of XON on 06/07/2019 at an average price of $5.24 a share.